LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 102.58% | 94.24% | 36.59% | 87.14% | 70.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.58% | 94.24% | 36.59% | 87.14% | 70.33% |
| Cost of Revenue | 149.66% | 166.96% | 79.63% | 84.51% | 92.10% |
| Gross Profit | -15.22% | -61.80% | -77.83% | 93.33% | 32.70% |
| SG&A Expenses | 57.82% | 60.96% | 90.94% | 65.51% | -10.00% |
| Depreciation & Amortization | 90.85% | 150.82% | -300.41% | 301.17% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 127.42% | 138.82% | 78.07% | 81.24% | 57.81% |
| Operating Income | -462.40% | -543.39% | -708.43% | 359.23% | 311.66% |
| Income Before Tax | -476.03% | -1,801.39% | -125.63% | -202.72% | 25.43% |
| Income Tax Expenses | -- | -- | -230.53% | -- | -- |
| Earnings from Continuing Operations | -476.03% | -1,801.39% | -124.46% | -202.72% | 25.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -476.03% | -1,801.39% | -124.46% | -202.72% | 25.43% |
| EBIT | -462.40% | -543.39% | -708.43% | 359.23% | 311.66% |
| EBITDA | -102.67% | -217.92% | -386.77% | 125.54% | 390.07% |
| EPS Basic | -433.33% | -1,700.00% | -123.47% | -192.00% | 33.33% |
| Normalized Basic EPS | -433.33% | -1,583.33% | -830.00% | 0.00% | 37.50% |
| EPS Diluted | -500.00% | -1,700.00% | -125.19% | -192.00% | 33.33% |
| Normalized Diluted EPS | -433.33% | -1,583.33% | -830.00% | 0.00% | 37.50% |
| Average Basic Shares Outstanding | 9.69% | 9.69% | 5.07% | 2.17% | 9.23% |
| Average Diluted Shares Outstanding | 9.69% | 9.75% | 5.07% | 1.99% | 9.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |